To search DNA methylation difference between monozygotic twins discordant for bipolar disorder, we applied a comprehensive genome scan method, methylation-sensitive representational difference analysis (MS-RDA) to lymphoblastoid cells derived from the twins. MS-RDA isolated 10 DNA fragments derived from 5 0 region of known genes/ESTs. Among these 10 regions, four regions showed DNA methylation differences between bipolar twin and control co-twin confirmed by bisulfite sequencing. We performed a case-control study of DNA methylation status of these four regions by pyrosequencing. Two regions, upstream regions of spermine synthase (SMS) and peptidylprolyl isomerase E-like (PPIEL) (CN265253), showed aberrant DNA methylation status in bipolar disorder. SMS, a gene on X chromosome, showed significantly higher DNA methylation level in female patients with bipolar disorder compared with control females. However, there was no difference of mRNA expression. In PPIEL, DNA methylation level was significantly lower in patients with bipolar II disorder than in controls. The expression level of PPIEL was significantly higher in bipolar II disorder than in controls. We found strong inverse correlation between gene expression and DNA methylation levels of PPIEL. These results suggest that altered DNA methylation statuses of PPIEL might have some significance in pathophysiology of bipolar disorder.
Introduction
Bipolar disorder is a mental disorder characterized by recurrent manic and depressive episodes affecting about 1% of the population. In spite of extensive studies, cause of bipolar disorder is unknown yet. Twin, adoption, family and linkage studies suggested that bipolar disorder is a complex disease caused by multiple genetic, environmental, or epigenetic risk factors. 1 Epigenetics is defined as (the study of) mitotically or meiotically heritable variations in gene function that cannot be explained by changes in DNA sequence. 2 Among epigenetic mechanisms, methylation of the cytosine residue of the DNA molecule has been well studied. Methylation of CpG islands controls gene expression, genomic imprinting and X-chromosome inactivation. Abnormality of DNA methylation status is involved in various pathological process. [3] [4] [5] Several lines of evidence suggested that epigenetics is relevant to bipolar disorder. Complex non-Mendelian inheritance, especially parent-of-origin effect, of bipolar disorder suggests the involvement of altered status of genomic imprinting and skewed X-chromosome inactivation. 6 Pharmacological studies also showed the possible role of DNA methylation in pathophysiology of bipolar disorder. Valproate, one of mood stabilizers, is known to be a histone deacetylase inhibitor. 7 Histone acethylation is coupled with DNA methylation and plays a role in the epigenetic regulation of gene expression. On the other hand, Sadenosyl methionine (SAM) is known to be effective for bipolar depression. 8 SAM supplies methyl residue in DNA methylation reaction, and enhance DNA methylation in vitro. 9 These data may suggest that epigenetic gene regulations may be relevant to the pathophysiology of bipolar disorder. Considering that DNA methylation may be involved in bipolar disorder, genome-wide screening for genes that is aberrantly methylated or demethylated in bipolar disorder is important.
In twin studies of bipolar disorder, the concordance rate in monozygotic twins ( > 65%) is much higher than in dizygotic twins ( > 14%). However, some monozygotic twins are discordant with respect to bipolar disorder. Such discordance between monozygotic twins could be arisen from epigenetic difference. 10 In this study, we focused on a pair of monozygotic twins discordant for bipolar disorder, which was reported in the previous report. 11 We previously searched for gene expression differences between these monozygotic twins. We found that XBP1 and its downstream gene, HSPA5, are commonly downregulated in the affected twins. 12 However, we could not identify differences of DNA sequence or DNA methylation of XBP1 between the twins. Expression differences of XBP1 might be caused by differential DNA methylation status and expression level of other genes, such as upstream genes of XBP1.
In this study, to comprehensively scan DNA methylation difference between the genomes of twins, we applied MS-RDA. 13 MS-RDA was developed by Ushijima et al. 13 and has been successfully used to identify the differences of DNA methylation status. We applied the MS-RDA method to lymphoblastoid cells derived from monozygotic twins discordant for bipolar disorder.
Materials and methods

Subjects
For MS-RDA, we examined the pair of monozygotic twins 49-year-old males discordant with respect to bipolar disorder. They were reported in a previous study. 12 The zygosity was determined by traditional phenotype markers such as blood types and HLA, micro-satellite markers and the extensive single nucleotide polymorphism (SNP) genotyping by DNA microarray (Human Mapping 50 K Xba Array, Affymetrix, Santa Clara, CA, USA). For real-time quantitative RT-PCR and pyrosequencing, we examined 16 unrelated patients with bipolar I disorder (BPI) (10 men and six women, 51.2712.6 (mean7s.d.) years old), seven unrelated patients with bipolar II disorder (BPII) (one men and six women, 62.779.2 years old) and 18 unrelated control subjects (12 men and six women, 45.6712.0 years old). They were the subjects from our previous study.
14 The patients were treated with various psychotropic drugs. Three of 16 BPI patients and none of seven BPII patients were treated with valproate.
For the additional analysis, an independent set of lymphoblastoid cells derived from 14 patients with bipolar II disorder in the Fujita Health University Hospital (four women and 10 men, 39.0713.5 (average7s.d.) years old) was used.
Consensus diagnosis was made by two psychiatrists according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (American Psychiatric Association, 1994) criteria using the non-structured interview and scrutinizing medical records. Control subjects were assessed by a psychiatrist after non-structured interview, and they had no major physical or mental disorders affecting social functioning. Subjects with a history of major mental disorders, and a family history of major mental disorders within first-degree relatives were excluded from the study. All the subjects were Japanese.
Written informed consent was obtained from all the subjects. This study was approved by the ethics committees of RIKEN and participating institutions.
Lymphoblastoid cells culture
Lymphocytes from peripheral blood were transformed by Epstein-Barr virus (EBV) using standard techniques as described before. 15 Briefly, lymphocytes were separated from peripheral blood and cultured with RPMI 1640 Medium (Sigma-Aldrich, St Louis, MO, USA) containing 20% fetal bovine serum (FBS) (GIBCO, Carlsbad, Ca, USA), Penicillin and streptomycin (50 mg/ml each) (GIBCO) and supernatant of B95-8 cell culture inducted by Epstein-Barr virus. These cells were passaged every week until the cell lines were established. The cells were passaged three times a week using similar medium except for the addition of 10% FBS. The cells were kept frozen until the experiment. The blood samples of the twins were obtained on the same day, and these samples were similarly handled. The lymphoblastoid cells for the case-control analysis were used after the same number of reculture.
DNA extraction
For MS-RDA, we used genomic DNA extracted from lymphoblastoid cells of monozygotic twins discordant with respect to bipolar disorder. For pyrosequencing, we used genomic DNA extracted from lymphoblastoid cell samples that RNA was used for the real-time quantitative RT-PCR. DNA was prepared by extraction with phenol and chloroform followed by ethanol precipitation. For the analysis of peripheral blood leukocytes, the red blood cells were lysed with hypotonic buffer and genomic DNA was extracted from the pellet.
Outline of MS-RDA MS-RDA was performed as described previously. 13 In MS-RDA, two genomes, tester and driver, were digested with HpaII, a methylation sensitive restriction enzyme. HpaII recognizes and digests 5 0 -CCGG-3 0 , but, is blocked by methylation of the internal C residue. After digestion, an adapter is ligated, and the entire restriction product is amplified by PCR. The PCR product is enriched with fragments originated from hypomethylated genomic regions that can be digested by HpaII. Thus, the amount of PCR product, in tester and driver, represents the DNA methylation status in each genome. After the first adapter is removed, a new adapter is ligated, only for the tester. The tester is mixed with the excess amount of driver product without the adapter. When there is no counterpart of a tester fragment in the driver, PCR product can be amplified from the tester. If there is counterpart in the driver, PCR amplification is suppressed by the driver products, because they can hybridize with the tester fragment, but cannot be amplified by PCR because of lack of adapter sequence. By repeating this procedure twice, DNA fragments derived from hypomethylated region only in the tester genome were selectively amplified. 16 MS-RDA Driver and tester genomes of 10 mg each were digested with 100 units of HpaII overnight. After phenol and chloroform extraction followed by ethanol precipitation, 1 mg of digestion product was ligated to 500 pmol of RHpa adapter by 800 units of T4 DNA Ligase (New England Biolabs (NEB), Berkley, MA, USA). RHpa adapter was prepared by annealing two oligonucleotides, RHpa24 and RHpa11. The ligation product was amplified by 25 cycles of PCR with RHpa24 oligonucleotide as primer as reported by Lisitsyn et al. 16 The RHpa adapter of the tester and driver amplicons was removed by digestion with HpaII and separation with gel filtration chromatography (CHROMA SPIN þ TE-200 Columns; Clontech Laboratories Inc., Mountain View, CA, USA). The JHpa adapter (500 pmol), which was prepared by annealing JHpa24 and JHpa11, was ligated to 200 ng of the tester amplicon with T4 DNA ligase. A 200 ng of the tester DNA with the JHpa adapter at its ends was mixed with 20 mg of the driver DNA. The DNA mixture was purified by phenol and chloroform extraction and ethanol precipitation and dissolved in 4 ml of 3 Â EE buffer (3 mM EDTA/3 mM N-(2-hydroxyethyl)pipecazine-N 0 -(3-propanesulfonic acid), pH 8.0), denatured at 961C for 10 min and reannealed at 671C overnight in the presence of 1 M NaCl. One-tenth of the reannealed product was amplified by PCR with the JHpa24 oligonucleotide as a primer for 10 cycles. DNA fragments linearly amplified, existing as singlestranded DNA, were digested with 100 units of Mung-Bean Nuclease, and the remaining doublestranded DNA was again amplified by PCR for 20 cycles with JHpa24 oligonucleotide.
The second cycle of competitive hybridization was performed by switching JHpa adapter to an NHpa adapter, which was prepared by annealing NHpa24 and NHpa11. A total of 20 ng of the product of the first cycle was mixed with 20 mg of driver DNA. Denaturing, reannealing and selective amplification of the self-annealed product were performed as for the first cycle. PCR products were purified by MinElute PCR Purification Kit (Qiagen, Valencia, CA, USA) and TA cloned using TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA, USA). Single bacterial colonies were subject to sequencing analysis. In total, 92 independent clones were analyzed. Using the obtained sequences, a homology search was performed with the BLAST program at a GenBank Web site.
Primers were as follows: RHpa24, 5
Bisulfite sequencing After denaturation, 1 mg of genomic DNA was treated with 3.6 M sodium bisulfite. The reaction was performed at 551C overnight. Genomic DNA was then purified with a wizard DNA clean-up system (Promega, Madison, WI, USA) and eluted with 50 ml of water. We typically used 1 ml of bisulfite-modified DNA for PCR. The CpG islands 17 were obtained through the UCSC (University of California, SantaCruz, CA, USA) Genome Browser (http://www.genome.ucsc. edu/index). Primer pairs were determined using Meth Primer software. 18 Primer pairs were as follows: PPIEL-1, 0 . PCR products were purified by MinElute PCR Purification Kit, and TA cloned using TOPO TA cloning kit. Single-bacterial colonies were subject to sequencing analysis.
RNA extraction and quantitative RT-PCR Total RNA was isolated by Trizol reagent (Invitrogen). After the DNase I treatment, 5 mg of total RNA was used for cDNA synthesis by oligo(dT) 12-18 primer and SuperScript II Reverse Transcriptase (RT) (Invitrogen).
Real-time quantitative RT-PCR using SYBR/GREEN I dye (Applied Biosystems, Foster city, CA, USA) was performed with ABI7900 (Applied Biosystems). After the denaturation at 951C for 5 min, the PCR conditions were 951C for 15 s and 601C for 1 min for 50 cycles. The comparative C t method was employed for quantification of transcripts according to the manufacture's protocol (User Bulletin #2, Applied Biosystems). Each sample was quantified in duplicate. Each experiment was repeated at least three times. Amplification of the single product was confirmed by monitoring the dissociation curve and by 3% agarose gel electrophoresis. Expression level of peptidylprolyl isomerase E-like (PPIEL) was also examined using commercially available cDNA (human brain parts tissue scan real-time, ORIGENE, Rockville, MD, USA). We used glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and cofilin 1 (CFL1) for normalization. Primer pairs for GAPDH and CFL1 have been shown previously. 19 Primer pairs used for qRT-PCR are as follows: PPIEL, 5 0 -TCGTGCCCATGACCACAG AG-3 0 and 5 0 -CGGTGGAAGCTGCTTCCCTT-3; SMS,
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Statistical analysis
Statistical analysis was performed using SPSS 11.0J software (SPSS Japan, Tokyo, Japan). Mann-Whitney U-test was employed for the analysis of expression levels and DNA methylation levels. Spearman's correlation coefficient was employed to examine the correlation between age and expression levels. One way analysis of variance (ANOVA) with the cofactors of age and sex was used to examine the effect of diagnosis controlling the confounding variables. P < 0.05 was considered significant.
Pyrosequencing
The PCR product of bisulfite-modified DNA was used for pyrosequencing analysis according to the manufacturer's standard protocol (Biotage, Uppsala, Sweden). Briefly, 4 ml of streptavidin-sepharose beads (Amersham Biosciences, Piscataway, NJ, USA) and 44 ml of binding buffer (10 mM Tris-HCl, 1 mM EDTA, 2 M NaCl, 0.1% Tween-20 at pH 7.6) were mixed with 40 ml of PCR product for 10 min at room temperature. The reaction mixture was placed onto a MultiScreen-HV, Clear Plate (Millipore, Billerica, MA, USA). After applying the vacuum, the beads were treated with a denaturation solution (0.2 N NaOH) for 1 min and washed twice with washing buffer (10 mM Tris-acetate at pH 7.6). The beads were then suspended with 50 ml of annealing buffer (20 mM Tris-acetate, 2 mM Mg-acetate at pH 7.6) containing 10 pmol of sequencing primer. The template-sequencing primer mixture was transferred onto a PSQ 96 Plate (Biotage), heated to 901C for 2 min and cooled to room temperature. Sequencing reactions were performed with a PSQ 96 SNP Reagent Kit (Biotage) according to the manufacturer's instructions. The percentage of methylation were calculated from the raw data using the allele quantification algorithm of the software provided by the manufacturer (PSQ96MA2.1.1 software, Biotage). 20 Each experiment was performed at least three times. The primer pairs and the analyzed sequences are as follows: PCR primer for PPIEL, 
Accession numbers
The DDBJ/EMBL/GenBank accession numbers of the sequences discussed in this paper are as follows: PIP5KL1, BC042184; SMS, BC009898; ARMC, BC039312; PPIEL, CN265253.
Results
Isolation of differentially methylated DNA fragments by MS-RDA Two independent series of MS-RDA was performed using genomic DNA extracted from lymphoblastoid cells of monozygotic twins discordant with respect to bipolar disorder. To search hypomethylated region in the patient with bipolar disorder, we used genome derived from bipolar twin as the tester genome and genome derived from control co-twin as the driver genome. PCR amplicons were prepared from HpaII digests of these two genomes (Figure 1a lanes 1 and  2) . As a result of the first cycle subtraction, one band was visible specifically in the subtracted products (Figure 1b lane 1 arrow) . After second cycle subtraction, this band was visible more clearly ( Figure 1c  lane 1 arrow) . After the two rounds of subtraction, products were cloned into TOPO vector and sequenced. A total of 51 DNA fragments were obtained. We obtained 21 DNA fragments derived from ribosomal DNA and four DNA fragments derived from mitochondrial DNA. This is in accordance with the initial paper of MS-RDA, showing that MS-RDA tends to amplify high copy number DNA, such as mitochondrial DNA, EB virus DNA, ribosomal DNA, LINE/SINE and repeat sequence. 13 These fragments were regarded as false positives. By sequencing and BLAST search at a Genbank web site, 26 nonredundant DNA fragments derived from human chromosome were obtained (Table 1) .
To search hypermethylated region in the bipolar patient, we also performed the other MS-RDA reaction, using the genome derived from control twin as the tester genome and genome derived from bipolar co-twin as the driver genome ( Figure 1a lanes 3 and  4) . As a result of this MS-RDA, a total of 41 DNA fragments were obtained. We obtained one DNA fragment derived from human chromosomal DNA, 34 DNA fragments derived from EB virus DNA, and six fragments derived from mitochondrial DNA ( Table 1) .
As a result of two independent series of MS-RDA, eight DNA fragments were derived from CGI located near the 5 0 region of known genes/ESTs, and two DNA fragments were derived from exon 1 of known genes/ ESTs. We focused on these 10 DNA fragments and further analyzed. In total of 10 DNA fragments, nine fragments were derived from putative hypomethylated region in the patient, and one fragment was derived from putative hypermethylated region in the patient. For genomic region around these 10 DNA fragments, we performed bisulfite sequencing to examine actual DNA methylation status (Figure 2 ). In four genomic regions, differences of DNA methylation status between bipolar twin and control cotwin were confirmed by bisulfite sequencing (Table 2) . In other six regions, we did not detect any difference of DNA methylation status.
Of four aberrant methylation regions, three were hypomethylated regions in the patient, while one was hypermethylated region in the patient. Fragment 1#57 was derived from putative promoter region of an EST, CN265253 (Figure 2a) . A homology search showed that CN265253 mRNA had high homology with peptidyl-prolyl cis-trans isomerase E (PPIE), or cyclophilin E. Because this gene is a partial duplication of PPIE and not the ortholog of mouse Ppie (see below), we named it as PPIEL (peptidylprolyl isomerase E-like). DNA methylation status of putative promoter region of PPIEL was analyzed by bisulfite sequencing. These regions were almost completely methylated in control twin. In contrast, these regions were globally hypomethylated in bipolar co-twin. Fragment 4#17 was derived from exon2 of the phosphatidylinositol-4-phosphate 5-kinase-like 1 (PIP5KL1) gene (Figure 2b ). This region was partially methylated in control twin, and completely demethylated in bipolar co-twin. Fragment 4#90 was derived from 5 0 region of the SMS gene (Figure 2c ). Between control twin and bipolar co-twin, DNA methylation status of this region was approximately the same excluding one CpG site (Figure 2c arrow) . This CpG site was completely methylated in control twin. In contrast, this site was completely unmethylated in bipolar co-twin. Fragment 4#86 was derived from 5 0 region of the Armadillo repeat containing 3 (ARMC3) gene (Figure 2d ). This region was unmethylated in control twin and partially methylated in bipolar co-twin.
Case-control studies of DNA methylation status in four candidate genes To examine whether or not these four aberrant DNA methylation statuses are seen in bipolar disorder in general, DNA methylation status was analyzed by pyrosequencing in the DNA derived from lymphoblastoid cells of 16 bipolar I disorder, seven bipolar II disorder and 18 control samples (Table 1) . Analyzed CpG sites by pyroseqencing were indicated by arrows and an arrowhead in Figure 1 . We found significant differences in methylation statuses of PPIEL and SMS, and these genes were further analyzed. PIP5KL1 and The results of the first cycle subtraction. We performed first subtraction of driver genome from tester genome (Subtraction þ ). As a control, we also performed PCR of tester genome without first subtraction (Subtraction À). After first subtraction, one band was visible specifically in the subtracted products in both series, B-C (Figure 1b , lane 1, arrow) and C-B (Figure 1b, lane 3, arrow) . These bands were visible more clearly after the second rounds of subtraction ( Figure 1c, lanes 1 and 3) . (c) The results of the second cycle subtraction. We performed second subtraction of driver genome from resultant of first subtraction (Subtraction þ ). As a control, we also performed PCR of resultant first subtraction without second subtraction (Subtraction À). After the two rounds of subtraction, products were cloned into TOPO vector and sequenced. 
ARMC3
were not methylated or only weakly methylated, in consistent with the results in twins. No significant differences between bipolar disorder and control samples were observed in DNA methylation statuses of PIP5KL1 (BPI, P = 0.72; BPII, P = 0.59) and ARMC3 (BPI, P = 0.94; BPII, P = 0.21).
DNA methylation status and expression level of SMS in bipolar disorder
The DNA methylation status of SMS was analyzed by pyrosequencing in the DNA of lymphoblastoid cells. Because SMS is located on X chromosome, one allele is assumed to be methylated due to X-chromosome inactivation. Thus, DNA methylation status was separately compared in male and female patients. Owing to small number of patients in each gender, bipolar I disorder and bipolar II disorder were combined in this analysis. Average DNA methylation level of SMS in 12 female patients with bipolar disorder (58.3711.5%; mean7s.d.) was significantly higher than that of six control females (35.4723.7%, P = 0.03) (Figure 3b ). This finding was basically similar even when a patient treated with valproate, which potentially affect histone acetylation and subsequently DNA methylation, is excluded (P = 0.05). No significant difference between patients with bipolar disorder and controls were observed in males (11 patients with bipolar disorder and 12 controls, P = 0.14), although there was non-significant but similar tendency to female patients (Figure 3a) . We found no significant correlations between age of control subjects and DNA methylation level of SMS in female patients (R = À0.476, P = 0.233, n = 6).
We also examined expression level of SMS using real-time quantitative RT-PCR. No significant differences between patients with bipolar disorder and controls were observed in male (P = 0.21) or female (P = 0.43) patients (Figure 3c and d) . The expression level of SMS was not correlated with DNA methylation status both in all male subjects (R = 0.26, P = 0.13) and all female subjects (R = 0.35, P = 0.12).
DNA methylation status and expression level of PPIEL in bipolar disorder
We analyzed DNA methylation status of five CpG sites in putative promoter region of PPIEL by pyrosequencing. The DNA methylation statuses of these all five CpG sites were significantly lower (P < 0.05) in patients with bipolar II disorder than that in controls. One-way ANOVA with cofactors of age and sex also showed significant effect of diagnosis (P < 0.05). Since these five sites showed similar results, we show the data of one site in the middle (Figure 2a arrowhead) as representative of five sites. The average DNA methylation status analyzed by pyrosequencing was significantly lower in patients with bipolar II disorder (51.879.1%) than that in controls (70.2710.3%, P = 0.001) (Figure 4a ). This result was not affected by valproate because none of patients with bipolar II disorder was treated with valproate. Patients with bipolar I disorder were not significantly different from controls (P = 0.96). No significant correlations were found between age in control subjects and DNA methylation level of PPIEL (R = À0.16, P = 0.53). There was no significant difference in the DNA methylation level of PPIEL with regard to gender in control subjects (P = 0.96).
We analyzed expression level of PPIEL using realtime quantitative RT-PCR normalized by GAPDH (Figure 4b ) and CFL1 (Figure 4c ). The expression level of PPIEL was significantly (P = 0.001) higher in patients with bipolar II disorder (PPIEL/GAPDH, 1.3 Â 10 ). No significant correlations were found between age in control subjects and DNA methylation level of PPIEL (R = 0.21, P = 0.41). There was no significant difference in the expression level of PPIEL with regard to gender (P = 0.50) or valproate treatment (CFL1 normalized, P = 0.25).
We also analyzed the DNA methylation status and expression of lymphoblastoid DNA of monozygotic twin discordant for bipolar disorder by pyrosequencing and real-time quantitative RT-PCR.
The DNA methylation status of bipolar twin (35-45%) was lower than that of control co-twin (80-100%), similarly to the results obtained by bisulfite sequencing (Figure 4d ). The expression level of PPIEL normalized with GAPDH was much higher in bipolar twin (5.2 Â 10 ). In all samples of bipolar I disorder, bipolar II disorder and controls, expression levels of PPIEL were inversely correlated with its DNA methylation level (P < 0.001, R = À0.81) near the 5 0 region of the PPIEL exon 1 (Figure 4e) . Expression levels were weakly, but inversely correlated with DNA methylation level near the exon 2 (P < 0.001, R = À0.54).
Because the number of patients with bipolar II disorder in the initial sample set is small (N = 7), we also examined 14 additional patients with bipolar II disorder (Fujita samples). We re-analyzed the DNA methylation status of PPIEL by pyrosequencing in the original samples and Fujita samples. The initial finding of lower DNA methylation level in bipolar II disorder (N = 7) compared with controls (N = 18) was replicated (controls: n = 18, 80.0711.9% (mean7s.d.); BPII: n = 7, 59.1710.2%, P = 0.001). The Fujita sample (14 patients with bipolar II disorder) also showed significantly lower DNA methylation level (68.0712.3%, P = 0.008) compared with controls ( Supplementary Figure 1) .
To test whether altered DNA methylation status of PPIEL is due to EBV transformation, we tested the relationship between the DNA methylation status in lymphoblastoid cells and that in peripheral leukocytes. When DNA methylation status of PPIEL was examined by pyrosequencing in seven healthy subjects whose leukocyte DNA is also available, methylation levels of five CpG sites in lymphoblastoid cells and those in peripheral leukocytes were significantly correlated with each other (P = 0.02, R = 0.41) (Figure 4f ).
Expression profiles of PPIEL in the human brain
If PPIEL is not expressed in the brain, pathophysiological significance of hypomethylation of this gene might be questioned. We could not visualize the distribution of PPIEL mRNA by in situ hybridization because this gene is not found in rodents. Instead, we examined the expression level of PPIEL in the human brain by quantitative RT-PCR using commercially available cDNA. The quantity level of mRNA of each gene was normalized with that of GAPDH. As a result, we found that PPIEL is ubiquitously expressed in the brain ( Figure 5 ). The expression is highest in the pituitary gland and substantia nigra, but relatively lower in the frontal cortex and hippocampus.
Discussion
DNA methylation difference between twins
In this study, we searched for DNA methylation difference between a pair of monozygotic twins discordant for bipolar disorder, and identified four genes with altered DNA methylation status between the twins. Because a recent study showed that DNA methylation difference in lymphocytes can be found between healthy monozygotic twins and it increases with aging, it is not easy to directly associate this finding with the discordant phenotype. 21 Thus, we performed a case-control analysis to search for the pathophysiological significance of this finding. We excluded a pathophysiological significance of two genes, PIP5KL1 and ARMC3, because there was no difference of DNA methylation status between patients with bipolar disorders and controls, and we studied the possible significance of other two genes further.
DNA methylation status of SMS at Xp22.11 was significantly different between female patients with bipolar disorder and female controls. However, lack of relationship between mRNA expression level and DNA methylation status, and no difference of mRNA levels between patients and controls, did not support the functional significance of the DNA methylation status of SMS. The DNA methylation difference initially detected in the twins can be attributed to only one CpG site, rather than global DNA methylation difference. In addition, the direction of DNA methylation difference observed in the case-control study was in the opposite direction to the finding in twins. These findings altogether do not support the role of altered DNA methylation status of SMS in pathophysiology of bipolar disorder.
On the other hand, in the case of PPIEL, both DNA methylation status and mRNA expression level were different between patients with bipolar II disorder and controls. The DNA methylation status was well correlated with mRNA expression level, and the DNA methylation difference found between twins is global DNA methylation status of several CpG sites, rather than a single CpG site. These findings support the possible functional significance of the DNA methylation at this site. The observed difference of DNA methylation status was not attributed to the difference of confounding factors such as age, gender and valproate treatment, although other confounding factors cannot be totally ruled out.
Because the number of samples of bipolar II disorder was small, we also examined an additional sample set (Fujita samples). Reduced DNA methylation status of PPIEL in bipolar II disorder was confirmed also in this sample set. However, we should cautiously interpret this finding because no control samples from Fujita Health University Hospital were available.
Pathophysiological significance of hypomethylation of PPIEL PPIEL is neighboring the BMP8A and OXCT2P genes. This region of human genome on 1p34.3 (BO1 locus) has the other region having high homology, carrying BMP8B and OXCT2 genes (BO2 locus). 22 This is supposed to be generated by segmental duplication that occurred before the primate-rodent split. However, the region containing PPIEL has been lost in mice. Thus, PPIEL is a primate-specific gene. PPIEL is predicted to encode a protein of 96 amino acids.
Although the putative open reading frame is shorter than PPIE, predicted amino-acid sequence of PPIEL partially maintains the peptidyl-prolyl cis-trans isomerase (PPI) domain. This gene has not been well characterized yet, and there is no clear evidence that it is translated into protein.
The function of PPI domain is to convert the stereological structure of proline assembled in a polypeptide. 23 PPI is known as a target of immunosuppressants such as cyclosporin A. In the case of cyclosporin A, its inhibition of PPI activity impairs proper folding of calcineurin, which causes inhibition of immunoreaction in T cells. 23 The function of PPIs depends on the target molecule, and it is difficult to identify the function of PPIEL at this stage. PPIEL was highly expressed in the pituitary gland and substantia nigra, but relatively lower in the frontal cortex and hippocampus. This suggests that PPIEL does not play a role in folding of ubiquitous molecules, but might be involved in specific neuronal function, such as dopamine neurotransmission or neuroendocrine systems.
Methodological considerations
It is not known how comprehensively the MS-RDA method can detect the DNA methylation difference. It is evident that this method can cause both falsenegative and false-positive findings. With regard to false negatives, the fragments that can be detected by this method depend on the types of restriction enzyme used. Thus, some of DNA methylation differences between twins might have been missed. With regard to false positives, many false-positive clones were detected as shown in Table 1 . Even among the 10 genomic regions around CpG island or exon 1 detected by MS-RDA, DNA methylation difference for six regions could not be validated by bisulfite sequencing method. In spite of these inherent problems, practical usefulness of MS-RDA as a method to screen aberrantly methylated genomic regions has been shown. 13 Indeed, new cancer-related aberrant DNA methylation has been discovered by this method.
Although we used lymphoblastoid cells in this study, the ideal source of DNA methylation analysis is undoubtedly the brain tissue. Indeed, several lines of evidence suggest the relationship between schizophrenia and aberrant DNA methylation of the reeling promoter causing its downregulation in the brain. 24, 25 We also reported that CpG island of SOX10 was highly methylated in the brains of patients with schizophrenia, correlating with reduced expression of SOX10. 26 However, it is practically impossible to use brain sample in the study of discordant twin.
Although the symptoms of bipolar disorder should be arisen from brain dysfunction, intermediate phenotype, such as abnormalities in Ca 2 þ levels, 27, 28 altered endoplasmic reticulum stress response 12 or altered inositol level, 29 have also been observed in lymphoblastoid cells. Thus, use of lymphoblastoid cells for epigenetic analysis may be validated at least in the study of bipolar disorder.
In addition, peripheral blood cells have already been used for epigenetic analysis of schizophrenia. Tsujita et al. 30 applied RLGS (restriction landmark genome scanning) method to analyze epigenetic difference between a pair of monozygotic twins discordant for schizophrenia, and identified differences between twins. McDonald et al. 31 used MS-RDA method to analyze a pair of monozygotic twins discordant for schizophrenia, but could not identify any difference. Petronis et al. 32 examined the DNA methylation status of the promoter of dopamine D2 receptor gene, and found that epigenetic distance is larger in a pair of discordant monozygotic twins compared with healthy monozygotic twins. Pathophysiological significance of the DNA methylation differences suggested in the previous studies is not well characterized yet, and thus usefulness of DNA methylation analysis in peripheral blood cells in mental disorders is still controversial. However, aberrant DNA methylation of an imprinted gene, KCNQ1OT1, identified in fibroblasts could also be identified in lymphocytes in monozygotic twins discordant for Beckwith Wiedemann syndrome. 33 Thus, at least aberrant imprinting status may be detectable even in peripheral blood cells. Otherwise, DNA methylation difference detected in this study might reflect the alteration of DNA methylation status occurred in the early developmental stage. In any case, the molecular mechanism of altered DNA methylation of PPIEL should be closely examined in the future.
In this study, we used lymphoblastoid cells transformed by EBV, rather than fresh lymphocytes, which potentially affect the results. By using lymphoblastoid cell lines, effects of medication can be eliminated by culturing the cells for more than 1 month after blood sampling, and cellular heterogeneity can be minimized. However, it cannot be ruled out that the effect of drugs lasts after in vitro culture for a long time. Although effect of valproate, which is reported to affect DNA methylation status, can be excluded in this study, effects of other drugs cannot be totally excluded.
It is suggested that EBV may alter the DNA methylation status of some genes, 34 but it has not been well characterized how and to what extent the EBV alters DNA methylation status. To exclude the effect of EBV, we analyzed methylation status of PPIEL in leukocytes of this pair of discordant twins. Similar to lymphoblastoid cells, bisulfite sequencing revealed that unmethylated allele of PPIEL was more frequently seen in affected twin (32%) compared with healthy co-twin (14%). Further, we found that the DNA methylation status in the lymphoblastoid cells was significantly correlated with that in peripheral leukocytes. These results support that hypomethylation of PPIEL observed in the lymphoblastoid cells of patients was not artificially caused by EBV but reflects the intrinsic inter-individual variability of DNA methylation status.
It should be noted that the number of subjects in this study is too small to draw a definite conclusion. Especially, the number of initial samples of patients with bipolar II disorder is very small (n = 7) and the second sample set is not large enough (n = 14). Thus, the results should be interpreted with caution. Nevertheless, this is the first study of altered DNA methylation status in bipolar disorder, which suggested a possible role of altered DNA methylation status in the pathophysiology of bipolar disorder.
Conclusion
In summary, we identified DNA methylation difference between monozygotic twins discordant for bipolar disorder using MS-RDA method. Hypomethylation of PPIEL found in the affected twin was confirmed in a case-control study. DNA methylation status of PPIEL was well correlated with mRNA expression levels.
These results suggest the possible role of PPIEL, in the pathophysiology of bipolar disorder, although it is not known whether it is the cause of the disease or the secondary or compensatory changes induced by the disease. This finding should be tested in a larger patient population, before it is applied to diagnostic testing or other clinical applications.
